Prophylaxis Of Bleeding Episodes In Hemophilia A And B Therapeutics
1. Qfitlia patent expiration
Treatment: Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients aged 12 years and older with hemophilia a or b with or without factor viii or ix inhibitors
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9376680 | GENZYME CORP | Serpinc1 iRNA compositions and methods of use thereof |
Mar, 2033
(7 years from now) | |
| US9127274 | GENZYME CORP | Serpinc1 iRNA compositions and methods of use thereof |
Mar, 2033
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11091759 | GENZYME CORP | Methods and compositions for treating a Serpinc1-associated disorder |
Dec, 2036
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 28, 2030 |
| Orphan Drug Exclusivity(ODE-510) | Mar 28, 2032 |
| Orphan Drug Exclusivity(ODE-511) | Mar 28, 2032 |
Drugs and Companies using FITUSIRAN SODIUM ingredient
NCE-1 date: 28 March, 2029
Market Authorisation Date: 28 March, 2025
Dosage: SOLUTION
More Information on Dosage
QFITLIA family patents
